US › Healthcare

Humacyte Inc (HUMA)

US · Healthcare · Biotechnology

$0.43-2.50%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$406,000

Revenue YoY

+34.9%

Net profit

$-36.8M

EPS

$-0.16

EPS estimate

$-0.10

Net margin

-9,064.5%

EPS came in at -0.16 against a street estimate of -0.10 — a miss of 60.0%.

Key statistics

Market cap

$119.2M

Forward P/E

35.8

P/B

5.01

Book value

$0.11

EPS (TTM)

$-0.51

52-week high

$1.90

52-week low

$0.34

50-day MA

$0.57

200-day MA

$0.84

Beta

2.44

Analyst view

Analysts rate Humacyte Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $1.62.

Shareholding

Insiders

5.67%

Institutions

26.87%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.64%
Antipodes Partners Limited	3.64%
Alyeska Investment Group, L.P.	2.17%
Davidson Kempner Capital Management LP	1.80%
BlackRock Inc	1.74%
Great Point Partners LLC	1.35%
UBS Group AG	1.02%
AQR Capital Management LLC	0.93%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Humacyte Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.